Loading...
Natalizumab and progressive multifocal leucoencephalopathy
Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natal...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Group
2006
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1798374/ https://ncbi.nlm.nih.gov/pubmed/17038473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2006.058404 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|